EICHOR
● Recruiting
A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Condition: Nonsmall Cell Lung Cancer · Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
About this study
HS-10365 is a small molecular, oral potent, selective RET inhibitor. The purpose of this study is to investigate the efficacy and safety of HS-10365 in Chinese advanced RET fusion-positive non-small cell lung cancer patients without any systemic therapy.
This description comes directly from the study's public registry record.
Talk to the study team
Shun Lu, MD · 13601813062 · shun_lu@hotmail.com
Always discuss trial participation with your own doctor first.
Locations (1)
| Shanghai Chest Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06147570